会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • COMPOUND
    • 复合
    • US20070225256A1
    • 2007-09-27
    • US11689936
    • 2007-03-22
    • Matthew LeeseAtul PurohitMichael ReedFabrice JourdanBarry Victor PotterChristian Bubert
    • Matthew LeeseAtul PurohitMichael ReedFabrice JourdanBarry Victor PotterChristian Bubert
    • A61K31/675A61K31/58C07J43/00C07J41/00
    • C07J43/003C07J3/00C07J7/0005C07J31/006C07J41/0005C07J41/0072
    • The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the A ring of the steroidal ring system is optionally substituted at position 2 or 4 with a group R4 which may be a suitable subtituent, wherein the D ring of the steroidal ring system is substituted by a group R2 of the formula -L-R3, wherein L is an optional linker group and R3 is selected from groups which are or which comprise one of (i) —SO2R5, wherein R5 is H, a hydrocarbyl group or a bond or group attached to the D ring; (ii) —NO2; (iii) —SOR6, wherein R6 is H or a hydrocarbyl group; (iv) —R7, wherein R7 is a halogen; (v) -alkyl; (vi) —C(═O)R3, wherein R3 is H or hydrocarbyl; (vii) —C≡CR9, wherein R9 is H or hydrocarbyl; (viii) —OC(═O)NR10R11 wherein R10 and R11 are independently selected from H and hydrocarbyl; (ix), (x), (xi), (xii) and (xiii) are formulae wherein when R3 is -alkyl, R4 is present as a hydrocarbon group, when R3 is —NO2R4 is present and/or R1 is present as a sulphamate group, and when R3 is —C(═O)R3R4 is present and R1 is present as a sulphamate group.
    • 本发明提供了包含甾族环系统和选自-OH,氨基磺酸盐基团,膦酸盐基团,硫代膦酸盐基团,磺酸盐基团或磺酰胺基团中的任何一个的任选基团R1的化合物; 其中所述甾族环系统的A环任选在位置2或4处被基团R 4取代,所述基团R 4可以是合适的取代基,其中所述甾族环系统的D环被基团 R L 3,其中L是任选的连接基团,R 3选自以下基团,或其中包含一个 的(i)-SO 2 R 5,其中R 5是H,连接到D环上的烃基或键或基团 ; (ii)-NO 2 2; (iii)-SOR 6,其中R 6是H或烃基; (iv)-R 7,其中R 7为卤素; (v) - 烷基; (vi)-C(-O)R 3,其中R 3是H或烃基; (vii)-C≡CR9,其中R 9是H或烃基; (viii)-OC(-O)NR 10 R 11,其中R 10和R 11独立地选自 由H和烃基组成; (ix),(x),(xi),(xii)和(xiii)是其中当R 3为 - 烷基时,R 4为烃, 当R 3为-NO 2 R 4存在时,和/或R 1存在作为 并且当R 3为-C(-O)R 3 3 R 4时,存在R 1和R 2 >以氨基磺酸盐基团存在。
    • 9. 发明授权
    • Compound
    • US08846737B2
    • 2014-09-30
    • US13392206
    • 2010-08-23
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • C07D249/08
    • C07D249/08C07D401/12C07D403/12C07D405/12C07D409/12
    • There is provided a compound of formula I wherein Z is selected from N and CR22, wherein R22 is H or a bond with D; wherein D is selected from a bond, C═O, and linear or branched hydrocarbon groups having a carbon chain of from 1 to 6 carbon atoms, wherein the carbon chain optionally contains an oxy group (═O), an ether (—O—) or thioether (—S—) link, wherein R1 is selected from: triazolyl, imidazolyl, pyrimidinyl radical wherein each of R2 to R6 is independently selected from —H, NO2, halo, —CN, —N[(C═O)0-1R12][(C═O)0-1R13] and —(CH2)0-1R14, or two adjacent groups of R2 to R6, together with the carbon atoms to which they are attached, form a ring, wherein at least one of R2 to R6 is —CN, wherein (i) at least one of R2 to R6 is —(CH2)0-1R14, or (ii) at least one of R2 to R6 is —N[(C═O)0-1R12][(C═O)0-1R13], or (iii) at least two adjacent groups of R2 to R6 together with the carbon atoms to which they are attached, form a ring, or (iv) at least one of R2 to R6 is —(CH2)0-1—O—R′14, wherein R12 and R13 are independently selected from H, linear or branched hydrocarbon groups having a carbon chain of from 1 to 10 carbon atoms, or together with the atoms to which they are attached, may form a mono or bicyclic ring having from 5 to 14 ring members wherein R14 is selected from: aliphatic ring systems unsubstituted or substituted monocyclic aliphatic heterocycles; unsubstituted or substituted heteroaryl radical, and unsubstituted or substituted phenyl group; the group of formula wherein t is 1 or 2 wherein R′14 is a unsubstituted or substituted phenyl group; wherein each of R7 to R11 is independently selected from —H, NO2, halo, —O—(C1-C6)haloalkyl, (C1-C6)haloalkyl, (C1-C6)alkyl, —CN, —OH, —OPh, —OBn, -Ph, —OSO2NR15R16, —SO2R26, —SO2NR27R28, —O—(C1-C6)alkyl, —(C═O)0-1NR29R30 and —CO(O)0-1R31; wherein R15 and R16 are independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups wherein each of R26 to R31 is independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups; or any pharmaceutically acceptable salts thereof.
    • 10. 发明申请
    • COMPOUND
    • US20120238550A1
    • 2012-09-20
    • US13392206
    • 2010-08-23
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • A61K31/4196C07D409/12C07D403/12A61K31/55C07D401/12A61P35/00C07D413/12A61K31/5377A61K31/496A61K31/4439C07D405/12C07D249/08A61K31/454
    • C07D249/08C07D401/12C07D403/12C07D405/12C07D409/12
    • There is provided a compound of formula I wherein Z is selected from N and CR22, wherein R22 is H or a bond with D; wherein D is selected from a bond, C═O, and linear or branched hydrocarbon groups having a carbon chain of from 1 to 6 carbon atoms, wherein the carbon chain optionally contains an oxy group (═O), an ether (—O—) or thioether (—S—) link, wherein R1 is selected from: triazolyl, imidazolyl, pyrimidinyl radical wherein each of R2 to R6 is independently selected from —H, NO2, halo, —CN, —N[(C═O)0-1R12][(C═O)0-1R13] and —(CH2)0-1R14, or two adjacent groups of R2 to R6, together with the carbon atoms to which they are attached, form a ring, wherein at least one of R2 to R6 is —CN, wherein (i) at least one of R2 to R6 is —(CH2)0-1R14, or (ii) at least one of R2 to R6 is —N[(C═O)0-1R12][(C═O)0-1R13], or (iii) at least two adjacent groups of R2 to R6 together with the carbon atoms to which they are attached, form a ring, or (iv) at least one of R2 to R6 is —(CH2)0-1—O—R′14, wherein R12 and R13 are independently selected from H, linear or branched hydrocarbon groups having a carbon chain of from 1 to 10 carbon atoms, or together with the atoms to which they are attached, may form a mono or bicyclic ring having from 5 to 14 ring members wherein R14 is selected from: aliphatic ring systems unsubstituted or substituted monocyclic aliphatic heterocycles; unsubstituted or substituted heteroaryl radical, and unsubstituted or substituted phenyl group; the group of formula wherein t is 1 or 2 wherein R′14 is a unsubstituted or substituted phenyl group; wherein each of R7 to R11 is independently selected from —H, NO2, halo, —O—(C1-C6)haloalkyl, (C1-C6)haloalkyl, (C1-C6)alkyl, —CN, —OH, —OPh, —OBn, -Ph, —OSO2NR15R16, —SO2R26, —SO2NR27R28, —O—(C1-C6)alkyl, —(C═O)0-1NR29R30 and —CO(O)0-1R31; wherein R15 and R16 are independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups wherein each of R26 to R31 is independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups; or any pharmaceutically acceptable salts thereof.